United Capital Financial Advisers LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 418,982 shares of the biopharmaceutical company’s stock after acquiring an additional 33,072 shares during the period. United Capital Financial Advisers LLC’s holdings in Gilead Sciences were worth $28,306,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its position in Gilead Sciences by 56.9% during the second quarter. Renaissance Technologies LLC now owns 12,740,248 shares of the biopharmaceutical company’s stock valued at $860,731,000 after buying an additional 4,620,000 shares during the period. Miller Howard Investments Inc. NY purchased a new stake in Gilead Sciences during the second quarter valued at about $93,386,000. First Trust Advisors LP boosted its position in Gilead Sciences by 77.8% during the second quarter. First Trust Advisors LP now owns 2,825,707 shares of the biopharmaceutical company’s stock valued at $190,905,000 after buying an additional 1,236,379 shares during the period. Holowesko Partners Ltd. purchased a new stake in Gilead Sciences during the second quarter valued at about $76,816,000. Finally, Banco Santander S.A. boosted its position in Gilead Sciences by 4,864.7% during the second quarter. Banco Santander S.A. now owns 932,219 shares of the biopharmaceutical company’s stock valued at $62,981,000 after buying an additional 913,442 shares during the period. Institutional investors own 79.89% of the company’s stock.
In related news, Director Olsen Per Wold sold 4,908 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $63.91, for a total value of $313,670.28. Following the completion of the transaction, the director now directly owns 102,762 shares of the company’s stock, valued at $6,567,519.42. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Brett A. Pletcher sold 608 shares of the stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $64.35, for a total transaction of $39,124.80. Following the completion of the transaction, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at $1,750,191.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,532 shares of company stock valued at $1,221,149. 0.20% of the stock is owned by insiders.
Several analysts have issued reports on GILD shares. Goldman Sachs Group lowered shares of Gilead Sciences from a “neutral” rating to a “sell” rating and cut their price target for the company from $70.00 to $60.00 in a research report on Tuesday, May 28th. Credit Suisse Group cut their price target on shares of Gilead Sciences from $70.00 to $67.00 and set a “neutral” rating for the company in a research report on Wednesday, July 31st. Oppenheimer set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Friday, July 12th. BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Friday. Finally, BMO Capital Markets set a $82.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, July 31st. Two analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average target price of $82.24.
GILD stock traded up $0.14 during trading on Friday, reaching $66.50. The company had a trading volume of 390,814 shares, compared to its average volume of 5,590,469. Gilead Sciences, Inc. has a 52 week low of $60.32 and a 52 week high of $79.61. The company has a market cap of $84.95 billion, a P/E ratio of 10.85, a PEG ratio of 3.18 and a beta of 1.10. The business has a 50 day moving average of $64.51 and a 200 day moving average of $65.44. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.76 and a quick ratio of 3.67.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.68 by $0.14. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The company had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.54 billion. During the same period in the prior year, the firm earned $1.91 earnings per share. Gilead Sciences’s revenue was down 2.8% on a year-over-year basis. Research analysts expect that Gilead Sciences, Inc. will post 6.66 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.79%. The ex-dividend date is Thursday, September 12th. Gilead Sciences’s payout ratio is currently 40.98%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: What is a Reverse Stock Split?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.